journal article·2019-07-31

Ambidextrous Approach To Disrupt Redox Balance in Tumor Cells with Increased ROS Production and Decreased GSH Synthesis for Cancer Therapy

Longfa Kou, Rui Sun, Shuyi Xiao, Yawen Zheng, Zhiwei Chen, Aimin Cai, Hailun Zheng, Qing Yao, Vadivel Ganapathy, Ruijie Chen

ACS Applied Materials & Interfaces· Volume 11· Issue 30
Publisher page

Abstract

An effective steady-state redox balance is maintained in cancer cells, allowing for protection against oxidative stress and thereby enhancing cell proliferation and tumor growth. Disruption of this redox balance would increase the cellular content of reactive oxygen species (ROS) and potentiate oxidative stress-induced cell death in tumor cells, thus representing an effective strategy for cancer treatment. Glutathione (GSH) is a major reducing agent, and its cellular levels are determined at least partly by the availability of cysteine via xCT (SLC7A11)-mediated entry of cystine into cells. We developed a nanoplatform using ZnO nanoparticles (NPs) as a carrier, loaded with salicylazosulfapyridine (SASP), and stabilized with DSPE-PEG, to form ultra-small NPs (SASP/ZnO NPs). The goal of this NP strategy is to disrupt the redox balance in cells by two mechanisms: increased generation of ROS and decreased synthesis of GSH. Such an approach would be effective in killing tumor cells. As expected, the SASP/ZnO NPs enhanced ROS production because of ZnO and impaired GSH synthesis because of SASP-induced inhibition of xCT (SLC7A11) transport function. As a consequence, treatment of tumor cells with SASP/ZnO NPs in vitro and in vivo resulted in a synergistic disruptive effect on redox balance in tumor cells and induced cell death and decreased tumor growth. This ambidextrous approach has potential in cancer therapy by combining two complementary pathways to disrupt the redox balance in tumor cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Sulfur Compounds in Biology · Nanoplatforms for cancer theranostics · Amino Acid Enzymes and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, China

Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, United States

School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China

Funding

Wenzhou Municipal Science and Technology Bureau · National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

References (37)

Show source-provided references
1. 10.1016/j.tcb.2017.11.00610.1016/j.tcb.2017.11.006 ↗
2. 10.1016/j.cmet.2015.12.00610.1016/j.cmet.2015.12.006 ↗
3. 10.1016/j.pharmthera.2008.09.00510.1016/j.pharmthera.2008.09.005 ↗
4. 10.1016/j.bbcan.2017.05.00310.1016/j.bbcan.2017.05.003 ↗
5. 10.1158/0008-5472.can-14-374510.1158/0008-5472.can-14-3745 ↗
6. 10.1016/j.bbamcr.2015.12.01710.1016/j.bbamcr.2015.12.017 ↗
7. 10.1089/ars.2011.441410.1089/ars.2011.4414 ↗
8. 10.1016/j.semcdb.2017.05.02310.1016/j.semcdb.2017.05.023 ↗
9. 10.1038/nrd400210.1038/nrd4002 ↗
10. 10.2165/11592590-000000000-0000010.2165/11592590-000000000-00000 ↗
11. 10.1016/j.redox.2014.02.00610.1016/j.redox.2014.02.006 ↗
12. 10.1016/j.cellsig.2013.08.00710.1016/j.cellsig.2013.08.007 ↗
13. 10.1016/j.freeradbiomed.2013.06.02010.1016/j.freeradbiomed.2013.06.020 ↗
14. 10.1007/s00441-005-0116-x10.1007/s00441-005-0116-x ↗
15. Bridges C. C. · Invest. Ophthalmol. Visual Sci. · 2001 · 42 · 47
16. 10.1089/ars.2011.439110.1089/ars.2011.4391 ↗
17. 10.1038/nature1434410.1038/nature14344 ↗
18. 10.1016/j.freeradbiomed.2018.09.04310.1016/j.freeradbiomed.2018.09.043 ↗
19. 10.1158/0008-5472.can-04-426710.1158/0008-5472.can-04-4267 ↗
20. 10.1016/j.tiv.2016.06.00510.1016/j.tiv.2016.06.005 ↗
21. 10.1021/acsami.7b1121910.1021/acsami.7b11219 ↗
22. 10.1517/17425247.2010.50256010.1517/17425247.2010.502560 ↗
23. 10.3390/nano804026810.3390/nano8040268 ↗
24. 10.1039/c7nr07677k10.1039/c7nr07677k ↗
25. 10.1021/acsami.7b0951110.1021/acsami.7b09511 ↗
26. 10.1021/acsami.7b1223310.1021/acsami.7b12233 ↗
27. 10.1021/acs.nanolett.8b0273210.1021/acs.nanolett.8b02732 ↗
28. 10.1016/j.tips.2018.06.00310.1016/j.tips.2018.06.003 ↗
29. 10.3389/fphar.2018.0002710.3389/fphar.2018.00027 ↗
30. 10.1021/acs.nanolett.8b0390510.1021/acs.nanolett.8b03905 ↗
31. 10.1002/anie.20171080010.1002/anie.201710800 ↗
32. 10.1016/j.scr.2013.09.01210.1016/j.scr.2013.09.012 ↗
33. 10.1016/j.tcb.2012.08.00210.1016/j.tcb.2012.08.002 ↗
34. 10.1002/stem.267110.1002/stem.2671 ↗
35. 10.3390/ijms1809184910.3390/ijms18091849 ↗
36. 10.1016/j.ccr.2011.01.03810.1016/j.ccr.2011.01.038 ↗
37. 10.1111/cas.1296710.1111/cas.12967 ↗